Rhonda Wallen

R. A. Wallen is the head of Corporate Development at Terumo BCT, the $1 billion biomedical division of Terumo Corporation, products and technologies for blood and cell-based therapies. With responsibility for strategic growth and alliances, Ms. Wallen is a member of the global Commercial Leadership Team and its working group on marketing excellence. She leads the evaluation and negotiation of a variety of US and international strategic transactions ranging from marketing alliances to equity investments. Prior to this she served as Chief Business Officer of Andarix Pharmaceuticals, a clinical stage oncology therapeutics company, and President of Caveo Therapeutics, a biotechnology company with reagent and therapeutic antibody product lines. In consulting roles with Cygnet Venture Management, she served as interim management for senior level business development and marketing functions, typically working with life science CEOs and founders to validate the strategic direction of start-up companies, articulate the core value proposition, define key milestones/use of proceeds, and complete corporate financings. Ms. Wallen was formerly an investment professional with Sequel Venture Partners, a venture fund with over $400M under management, where she invested over $10M of capital into successful life science companies. Ms. Wallen serves on 4 corporate and advisory boards, including Director at Boulder Community Health. She holds an undergraduate degree in Biological Sciences from Stanford University, and graduate degrees in molecular biology and business from the University of Rochester School of Medicine and Dentistry and Simon School of Business, respectively.